Anavex Life Sciences Corp (AVXL)
US$ 8.951.24%
Price Chart
Key Statistics
Market Cap
$ 720.54M
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
349.93K
52W High
$ 14.44
52W Low
$ 3.51
Dividend Yield
0.00%
Beta
0.82
Technicals
50-Day MA
8.914
200-Day MA
8.006
52 Week High
14.4405
52 Week Low
3.51
About AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States.
Employees
42
Headquarters
New York, NY
CEO
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Latest News
Anavex: A Small Bit Of Progress Against Alzheimer's Disease - Seeking Alpha
2025-04-13 • Google News
(AVXL) Investment Analysis - news.stocktradersdaily.com
3 days ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg